Pine Bark Extract for Blood Pressure & Circulation: A Realistic Result

By Erin Rose · Updated July 19, 2026 · Methodology

Informational summary of published research — not medical advice. Never reduce or stop prescribed blood pressure, antiplatelet, or anticoagulant medication based on this page. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Fogacci 2020: the strictest filter, the null result

Fogacci 2020 is a PRISMA-compliant, PROSPERO-registered meta-analysis (CRD42018112172) restricted to 7 randomized, double-blind, placebo-controlled trials, N=626 — the strictest inclusion filter of the three. PRIMARY ENDPOINTS were SBP, DBP, mean arterial pressure, and pulse pressure — NOT MET on any of them: "the present meta-analysis does not suggest any significant effect of pycnogenol on BP." SBP moved a statistically meaningless −0.028 mmHg (p=.726); DBP −0.144 mmHg (p=.067). The null result held in a leave-one-out sensitivity analysis, meaning no single trial was driving it. The likely explanation for why this is the one null meta-analysis: only 7 trials met its strict double-blind/placebo-controlled/RCT filter, a much narrower pool than the other two.

Pourmasoumi 2020: a modest positive, with a caveat that undercuts it

Pourmasoumi 2020 pooled 12 trials, N=922. PRIMARY ENDPOINT was SBP/DBP — MET, modestly: SBP down 3.22 mmHg (95% CI −5.52 to −0.92), DBP down 1.91 mmHg (95% CI −3.64 to −0.18). But the subgroup findings undercut a clean "it works" story: the systolic effect was "more pronounced" when Pycnogenol was co-administered with other treatments, not as monotherapy, and the diastolic effect was significant only in trials lasting longer than 12 weeks, not shorter ones. The authors' own conclusion calls for "further, high quality randomized clinical trials" — an implicit admission the current evidence base isn't there yet.

Zhang 2018: the honesty citation that undercuts its own headline

Zhang 2018 pooled 9 trials, N=549, doses 150–200mg/day. PRIMARY ENDPOINT was SBP/DBP — MET in the pooled result: SBP down 3.22 mmHg (95% CI −6.20 to −0.24), DBP down 3.11 mmHg (95% CI −4.60 to −1.62), with larger reductions in hypertensive participants and longer trials. But this is the single most important honesty citation on this page: the paper's own conclusion states "this significant reduction was not observed in well-designed trials" — the authors themselves attribute the pooled positive result to the lower-methodological-quality trials in their pool, not to the well-designed ones. A positive meta-analysis whose own text undercuts its headline finding.

Three overlapping trial pools, three different verdicts — that disagreement, not any single number, is the honest state of the blood-pressure evidence for pine bark extract.

Drieling 2010: the independent counterweight

Pooled meta-analyses of small, sometimes-industry-adjacent trials can look more settled than any individual well-designed study supports. Drieling 2010 is the clearest corrective in this evidence base: a randomized, double-blind, placebo-controlled RCT (n=130 adults with elevated CVD risk), Stanford Prevention Research Center, NCT00425945 — genuinely independent, non-industry, academic. PRIMARY ENDPOINT was blood pressure (sum of SBP+DBP) — NOT MET: −1.0 mmHg in the pine-bark group vs −1.9 mmHg in placebo (p=.87). No significant effect on BMI, lipids, liver enzymes, LDL particle size, insulin, Lp(a), or hs-CRP, in the whole group or any subgroup. The authors' own conclusion: "our results are consistent with a general failure of antioxidants to demonstrate cardiovascular benefits." One important caveat: this trial used a different, non-Pycnogenol pine bark extract (Flavagenol/Toyo-FVG), so it can't be read as proof Pycnogenol itself fails — but it is the clearest independent null RCT for "pine bark extract" as a category.

Enseleit 2012: the strongest single study, on a different endpoint

Enseleit 2012 is the best mechanistic human evidence in this entire pack, and it's genuinely independent: University Hospital Zürich, not industry-run. Double-blind, randomized, placebo-controlled, cross-over RCT, n=23 completers, stable coronary artery disease patients on standard cardiovascular therapy, Pycnogenol 200mg/day for 8 weeks vs placebo (2-week washout between arms). PRIMARY ENDPOINT was flow-mediated dilation (FMD) of the brachial artery — a direct measure of endothelial function — MET: FMD improved from 5.3±2.6 to 7.0±3.1 with Pycnogenol (p<0.0001) vs no meaningful change with placebo, a between-group treatment effect of +2.75 (95% CI 1.75–3.75, p<0.0001). The oxidative-stress marker 15-F2t-isoprostane also significantly decreased. But note what it did NOT find: no significant change in inflammation markers, platelet adhesion, or 24-hour ambulatory blood pressure itself. This is a real, specific, mechanistically coherent endothelial-function signal — not proof of a blood-pressure effect, and the trial was small (n=23), single-center, with short 8-week arms.

As an Amazon Associate we earn from qualifying purchases. Ranked by genuine-vs-generic status, never commissions.

Frequently asked questions

Related

• Pine Bark Extract: what it is & who it's for
• Dosage Guide — the trial dose range, honestly
• Best Pine Bark Extract Supplement — genuine Pycnogenol® vs generic
• Pycnogenol vs Generic Pine Bark Extract
• Does Grape Seed Extract Actually Lower Blood Pressure? — the sibling OPC-extract evidence reckoning
• Garlic for Blood Pressure — another cardiovascular botanical with real but modest evidence

Sources